Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine: follow-up from months 12–24 in a Phase III …
MH Einstein, M Baron, MJ Levin, A Chatterjee… - Human …, 2011 - Taylor & Francis
In this observer-blind study (NCT00423046), women (N= 1,106), stratified by age (18–26, 27–
35, 36–45 years), were randomized (1: 1) to receive the HPV-16/18 vaccine (Cervarix® …
35, 36–45 years), were randomized (1: 1) to receive the HPV-16/18 vaccine (Cervarix® …
Comparison of long-term immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy women …
MH Einstein, P Takacs, A Chatterjee… - Human vaccines & …, 2014 - Taylor & Francis
The observer-blind, randomized, age-stratified, head-to-head study (NCT00423046)
comparing immunogenicity and safety of HPV-16/18 and HPV-6/11/16/18 vaccines in …
comparing immunogenicity and safety of HPV-16/18 and HPV-6/11/16/18 vaccines in …
Comparative humoral and cellular immunogenicity and safety of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and HPV-6/11/16/18 vaccine in healthy …
MH Einstein, MJ Levin, A Chatterjee… - Human vaccines & …, 2014 - Taylor & Francis
We previously reported higher anti-HPV-16 and-18 immune responses induced by HPV-
16/18 vaccine compared with HPV-6/11/16/18 vaccine at Month 7 (one month after …
16/18 vaccine compared with HPV-6/11/16/18 vaccine at Month 7 (one month after …
Comparison of the immunogenicity of the human papillomavirus (HPV)-16/18 vaccine and the HPV-6/11/16/18 vaccine for oncogenic non-vaccine types HPV-31 and …
MH Einstein, M Baron, MJ Levin, A Chatterjee… - Human …, 2011 - Taylor & Francis
Protection against oncogenic non-vaccine types (cross-protection) offered by human
papillomavirus (HPV) vaccines may provide a significant medical benefit. Available clinical …
papillomavirus (HPV) vaccines may provide a significant medical benefit. Available clinical …
[HTML][HTML] Immunogenicity and safety of two novel human papillomavirus 4-and 9-valent vaccines in Chinese women aged 20–45 years: a randomized, blinded …
Y Shu, Y Yu, Y Ji, L Zhang, Y Li, H Qin, Z Huang, Z Ou… - Vaccine, 2022 - Elsevier
Background Human papillomavirus (HPV) infections were the main cause of anogenital
cancers and warts. HPV 6/11/16/18 vaccines provide protection against the high-risk types …
cancers and warts. HPV 6/11/16/18 vaccines provide protection against the high-risk types …
Durability of protection afforded by fewer doses of the HPV16/18 vaccine: the CVT trial
M Safaeian, JN Sampson, Y Pan… - JNCI: Journal of the …, 2018 - academic.oup.com
Background Previously, we demonstrated similar human papillomavirus (HPV) 16/18
vaccine efficacy estimates and stable HPV16/18 antibody levels four years postvaccination …
vaccine efficacy estimates and stable HPV16/18 antibody levels four years postvaccination …
Immunogenicity and safety of a nine-valent human papillomavirus vaccine in women 27–45 years of age compared to women 16–26 years of age: An open-label …
EA Joura, A Ulied, C Vandermeulen, MR Figueroa… - Vaccine, 2021 - Elsevier
Background Efficacy of the nine-valent human papillomavirus (9vHPV; HPV types
6/11/16/18/31/33/45/52/58) vaccine was demonstrated in a phase 3 study in women 16–26 …
6/11/16/18/31/33/45/52/58) vaccine was demonstrated in a phase 3 study in women 16–26 …
Efficacy of the human papillomavirus (HPV)‐16/18 AS04‐adjuvanted vaccine in women aged 15–25 years with and without serological evidence of previous exposure …
A Szarewski, WAJ Poppe, SR Skinner… - … journal of cancer, 2012 - Wiley Online Library
Abstract In the Phase III PATRICIA study (NCT00122681), the human papillomavirus (HPV)‐
16/18 AS04‐adjuvanted vaccine (Cervarix®, GlaxoSmithKline Biologicals) was highly …
16/18 AS04‐adjuvanted vaccine (Cervarix®, GlaxoSmithKline Biologicals) was highly …
Ten‐year immune persistence and safety of the HPV‐16/18 AS 04‐adjuvanted vaccine in females vaccinated at 15–55 years of age
TF Schwarz, A Galaj, M Spaczynski, J Wysocki… - Cancer …, 2017 - Wiley Online Library
Women remain at risk of human papillomavirus (HPV) infection for most of their lives. The
duration of protection against HPV‐16/18 from prophylactic vaccination remains unknown …
duration of protection against HPV‐16/18 from prophylactic vaccination remains unknown …
Evaluation of quadrivalent HPV 6/11/16/18 vaccine efficacy against cervical and anogenital disease in subjects with serological evidence of prior vaccine type HPV …
SE Olsson, SK Kjaer, K Sigurdsson, OE Iversen… - Human …, 2009 - Taylor & Francis
Objective In the quadrivalent (types 6/11/16/18) HPV vaccine (GARDASIL®/SILGARD®)
clinical program, 73% of women aged 16-26 were naïve to all vaccine HPV types. In these …
clinical program, 73% of women aged 16-26 were naïve to all vaccine HPV types. In these …